Bernhard Ehmer

Dr. Ehmer has been a member of Affimed’s Supervisory Board since 2016. In May 2022, he has been elected to chair the board of directors and as member of the audit committee of Biotest AG, where he already served as chairman of the board of management until April 2019. Furthermore he is on the Board of Directors at Achilles Therapeutics since May 2022. Dr. Ehmer served as chairman of the board of directors at Symphogen A/S, Denmark until June 2020. Prior to this, he worked for the Imclone Group, a wholly owned subsidiary of Eli Lilly, as President of Imclone Systems Corporation in the United States and as managing director in Germany.

In 2007/2008 he was CEO of Fresenius Biotech, Germany and before this, Dr. Ehmer headed the Business Area Oncology of Merck KGaA, Darmstadt and served as head of Global Clinical Operations at Merck. Between 1986 and 1998 he held various functions at Boehringer Mannheim in Germany, Italy and Singapore. Dr. Ehmer holds a degree in medicine and worked in the Department of Internal Medicine at the Academic Teaching Hospital of the University of Heidelberg.